A phase III, multicenter, open-label, randomized trial (PROOF 301; NCT03773302) of infigratinib in comparison to gemcitabine/cisplatin in patients with advanced or metastatic CCA with FGFR2 translocations is ongoing. This evidence concerns the gene FGFR2 and cholangiocarcinoma.